1108TiP - Chemoradiotherapy versus radiotherapy in the treatment of salivary glands and nasal tumors: the GORTEC 2016-02 study

F.R. Ferrand, J. Thariat, N. Vulquin, V. Calugaru, O. Malard, C. Murariu, F. Janot, F. Louat, C. Michel, J. Bourhis

Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374

Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing SGC

L.D. Locati, C. Caballero, C. Fortpied, F. Perrone, S. Pilotti, K.J. Harrington, V. Grégoire, L. Licitra

Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374

Dose escalation of radiotherapy (RT) for locally advanced head and neck carcinomas treated with concomitant chemotherapy (CT) and RT: Results of the GORTEC 2004-01 randomized trial.

Jean Bourhis, Anne Auperin, Marc Alfonsi, xu Shan Sun, Michel Rives, Yoann Pointreau, Cedrik Lafond, Pierre Boisselier, Pierre Graff, Juliette Thariat, Yungan Tao

J Clin Oncol 35, 2017 (suppl; abstr 6015)

Impact of p16 expression on induction taxotere-cisplatin-5 FU (TPF) followed by cetuximab-radiotherapy in N2b-N3 head and neck squamous cell carcinoma (HNSCC): Results of GORTEC 2007-02 phase III randomized trial.

Yungan Tao, Lionnel Geoffrois, Laurent Martin, Dominique De Raucourt, Joelle Miny, Philippe Maingon, Cedrik Lafond, Claude Tuchais, Christian Sire, Emmanuel Babin, Alexandre Coutte, Frederic Rolland, Marie-Helene Girard-Calais, Odile Casiraghi, Pascal Garaud, Jean Bourhis

J Clin Oncol 35, 2017 (suppl; abstr 6070)